What is the revenue and EPS growth rate for Myomo year over year?

What is Myomo's gross profit margin?

What factors drove the changes in Myomo's revenue and profit?

What guidance did Myomo's management provide for the next earnings period?

What does Myomo do and what are its main business segments?

What is the market's earnings forecast for Myomo next quarter?

What were the key takeaways from Myomo’s earnings call?

What is Myomo's latest dividend and current dividend yield?

- **Revenue Growth**: $10.1M (+10% YoY), driven by 63% international surge and 154% O&P channel expansion
- **Pipeline Momentum**: 1,669 patients (+32% YoY), 826 new adds (+28% YoY)
- **Strategic Shifts**: TV ads reduce CAC, MyoConnect referrals up 50%, O&P channel now 9% of revenue
- **Financial Health**: $17.5M term loan reduces dilution, targeting $16M breakeven
- **Margin Challenges**: Gross margin 63.8% (-11.6pts YoY), operating loss $3.5M
- **International Success**: Germany accounts for 18% of revenue, China JV in clinical trial

**【CEO Opening Remarks】**
- Q3 2025 revenue of $10.1 million, up 10% YoY, driven by record international sales ($1.8M, +63%) and O&P channel growth ($900K, +154%).
- Pipeline increased 32% YoY to 1,669 patients, with 826 new adds (+28% YoY, +1% QoQ).
- Key initiatives: 
  1. Shift to TV advertising reduced cost per qualified lead
  2. MyoConnect program generating high-quality clinical referrals
  3. Expanded O&P channel in U.S. and Germany
  4. Manufacturing cost reductions
- Reiterated 2025 guidance of $40-42M revenue (+23% YoY)

**【CFO Financial Commentary】**
- Revenue units: 186 (+16% YoY), 57% from intra-quarter fills
- ASP: $54,300 (-5% YoY, +3% normalized for Medicare accounting change)
- Gross margin: 63.8% (-11.6pts YoY) due to higher labor and overhead
- Operating expenses: $10M (+26% YoY) driven by R&D and marketing
- Net loss: $3.7M (-73% YoY) with cash burn of $2.9M
- New $17.5M term loan facility to reduce reliance on equity

**【Q&A Highlights】**
- **O&P Channel Scale**: 30 units shipped in Q3, targeting 20+ clinics in U.S.
- **Customer Acquisition**: TV ads 3x more cost-effective than social media
- **Pipeline Quality**: 45% of adds now from clinical referrals vs. direct ads
- **Gross Margin Outlook**: 200bps improvement possible with scale
- **Breakeven Target**: $16-17M quarterly revenue with current cost structure
- **Germany Growth**: 100+ O&P partners driving 18% of total revenue
- **China JV**: Clinical trial ongoing, no near-term impact

Myomo, Inc. (MYO) Q3 2025 Earnings Call Transcript

Revenue

Sales and Services Revenue

Financing Services Revenue

Other Revenue

Cost of Revenue

Cost of Goods and Services

Cost of Financing Services

Other Cost

Gross Profit

Other Operating Income

Operating Expenses

Selling, General and Administrative Expenses

Selling and Marketing Expenses

General and Administrative Expenses

Research and Development Expenses

Loss on Bad Debts

Loss on Impairment of Other Assets

Loss on Disposal of Assets

Other Operating Expenses

Operating Income

Non-Operating Income (Loss)

Income (Loss) from Affiliates

Income (Loss) from Associates

Income (Loss) from Joint ventures

Gain (Loss) on Other Investment

Gain (Loss) on Change in Fair Value

Gain (Loss) on Foreign Currency Exchange

Other Non-Operating Income (Loss)

Net Interest Expense

Interest Expense

Interest Income

Pretax Income From Continuing Operations

Income Tax Expense

Current Income Tax

Deferred Income Tax

Income Tax Adjustments

Net Income from Continuing Operations

Income from Discontinued Operations

Other Items Before Net Income

Net Income

Net Income Attributable to Minority Interests

Net Income Attributable to Owners of the Company

Preferred Stock Dividends

Other Adjustments

Net Income Attributable to Common Stockholders

Other Comprehensive Income

Total Comprehensive Income

Total Comprehensive Income Attributable to Minority Interests

Total Comprehensive Income Attributable to Owners of the Company

Basic EPS

Basic EPS from Continuing Operations

Basic EPS from Discontinued Operations

Diluted EPS

Diluted EPS from Continuing Operations

Diluted EPS from Discontinued Operations

MYO

MYO fundamentals

You can ask Aime